Prospective feasibility study of amrubicin and bevacizumab therapy for patients with previously treated advanced NSCLC
H Imai, K Kaira, I Naruse, N Kasahara… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: The efficacy of the combination of amrubicin and bevacizumab against
advanced non small-cell lung cancer (NSCLC), as a second or third-line treatment, was …
advanced non small-cell lung cancer (NSCLC), as a second or third-line treatment, was …
[HTML][HTML] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
H Yoshioka, N Katakami, H Okamoto, Y Iwamoto… - Annals of …, 2017 - Elsevier
Background Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and
small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a …
small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a …
Dose Escalation and Feasibility Study of Amrubicin Combined With Cisplatin in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
N Yoshimura, T Kimura, S Mitsuoka… - American journal of …, 2013 - journals.lww.com
Objectives: Cisplatin is a key drug used in the treatment of non–small cell lung cancer
(NSCLC), and amrubicin is one of the new active agents for NSCLC. The objective of this …
(NSCLC), and amrubicin is one of the new active agents for NSCLC. The objective of this …
Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer
S Igawa, J Sasaki, M Ishihara, S Otani, S Maki… - Chemotherapy, 2013 - karger.com
Background: Currently, there are no standard cytotoxic treatments for non-small-cell lung
cancer (NSCLC) patients beyond third-line therapy. The purpose of this study was to …
cancer (NSCLC) patients beyond third-line therapy. The purpose of this study was to …
Amrubicin for non-small-cell lung cancer and small-cell lung cancer
T Kurata, I Okamoto, K Tamura, M Fukuoka - Investigational new drugs, 2007 - Springer
Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II
inhibitor. Recently, amrubicin was approved in Japan for the treatment of small-and non …
inhibitor. Recently, amrubicin was approved in Japan for the treatment of small-and non …
Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer
T Shimokawa, M Shibuya, K Kitamura… - International journal of …, 2009 - Springer
Background Amrubicin, a totally synthetic 9-aminoanthracycline, was evaluated
retrospectively for the treatment of refractory and relapsed small-cell lung cancer (SCLC) …
retrospectively for the treatment of refractory and relapsed small-cell lung cancer (SCLC) …
Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens
S Igawa, T Takahashi, Y Nakamura, A Tsuya… - Anticancer …, 2008 - ar.iiarjournals.org
Background: No investigation of amrubicin monotherapy in pre-treated advanced non-small
cell lung cancer (NSCLC) patients has yet been reported. Patients and Methods: The …
cell lung cancer (NSCLC) patients has yet been reported. Patients and Methods: The …
Efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy
M Saigusa, K Asada, T Akamatsu, Y Tanaka… - Oncology Research …, 2019 - karger.com
Background: There are no standard cytotoxic treatments for non-small-cell lung cancer
(NSCLC) patients beyond third-line therapy. The purpose of this study was to evaluate the …
(NSCLC) patients beyond third-line therapy. The purpose of this study was to evaluate the …
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study
S Habib, J Delourme, X Dhalluin, G Petyt, N Tacelli… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic
effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has …
effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has …
[HTML][HTML] Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial …
H Kaneda, I Okamoto, H Hayashi, H Yoshioka… - Journal of Thoracic …, 2010 - Elsevier
Background Amrubicin is a synthetic anthracycline drug that is a potent inhibitor of
topoisomerase II. We have performed a multicenter phase II trial to evaluate the efficacy and …
topoisomerase II. We have performed a multicenter phase II trial to evaluate the efficacy and …